Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889106 | 1.00 | TDP1 (0.35) | TDP1 | |
| SCHEMBL4487307 | 0.89 | — | — | |
| SCHEMBL4487319 | 0.89 | — | — | |
| SCHEMBL821115 | 0.89 | — | — | |
| SCHEMBL10955986 | 0.83 | — | — | |
| SCHEMBL10960047 | 0.80 | — | — | |
| SCHEMBL8424445 | 0.80 | — | — | |
| SCHEMBL7497634 | 0.80 | — | — | |
| SCHEMBL14966263 | 0.80 | — | — | |
| SCHEMBL12189897 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ZC3HAV1, EIF2AK2, POLRMT | TDP1 2279/4885 |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ZC3HAV1, HAVCR2, HCCS | TDP1 3396/4885 |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, ZC3HAV1, POLRMT | TDP1 2246/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | TDP1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.